Pasar al contenido principal

ESTUDIO DEL METABOLISMO DEL ADN Y LAS BIOPELICULAS POLIMICROBIANAS PARA EL DESARROLLO DE TERAPIAS MAS EFICIENTES CONTRA LAS INFECCIONES BACTERIANAS

PID2021-125801OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Antimicrobial and antibiofilm activity of human recombinant H1 histones against bacterial infections

  • Arévalo-Jaimes, Betsy Verónica|||0000-0002-3363-5403
  • Salinas-Pena, Mónica|||0000-0001-8134-7038
  • Ponte Marull, Immaculada|||0000-0002-9448-6915
  • Jordan, Albert|||0000-0002-3970-8693
  • Roque Córdova, Alicia|||0000-0002-6206-6481
  • Torrents, Eduard|||0000-0002-3010-1609
Histones possess significant antimicrobial potential, yet their activity against biofilms remains underexplored. Moreover, concerns regarding adverse effects limit their clinical implementation. We investigated the antibacterial efficacy of human recombinant histone H1 subtypes against Pseudomonas aeruginosa PAO1, both planktonic and in biofilms. After the in vitro tests, toxicity and efficacy were assessed in a P. aeruginosa PAO1 infection model using Galleria mellonella larvae. Histones were also evaluated in combination with ciprofloxacin (Cpx) and gentamicin (Gm). Our results demonstrate antimicrobial activity of all three histones against P. aeruginosa PAO1, with H1.0 and H1.4 showing efficacy at lower concentrations. The bactericidal effect was associated with a mechanism of membrane disruption. In vitro studies using static and dynamic models showed that H1.4 had antibiofilm potential by reducing cell biomass. Neither H1.0 nor H1.4 showed toxicity in G. mellonella larvae, and both increased larvae survival when infected with P. aeruginosa PAO1. Although in vitro synergism was observed between ciprofloxacin and H1.0, no improvement over the antibiotic alone was noted in vivo. Differences in antibacterial and antibiofilm activity were attributed to sequence and structural variations among histone subtypes. Moreover, the efficacy of H1.0 and H1.4 was influenced by the presence and strength of the extracellular matrix. These findings suggest histones hold promise for combating acute and chronic infections caused by pathogens such as P. aeruginosa.
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

The study of immunological markers in tuberculosis across animal models and its translation to human research

  • Díaz-Fernández, Sergio
  • Aleluia, Matilde
  • Saraiva, Margarida
  • Soldevilla, Pablo
  • Torrelles, Jordi B.
  • Sharan, Riti
  • Verreck, Frank A. W.
  • Izzo, Angelo
  • Vidal, Maria
  • Moreira, Ana C.
  • Pérez de Val, Bernat
  • Roca, Francisco Jose
  • Preda, Madalina
  • Torrents, Eduard
  • Julián, Esther
  • Domínguez, José
  • Latorre, Irene
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, remains one of the major causes of death from infection worldwide, with over a million associated deaths each year. The study of biomarkers for TB is critical for advancing our understanding and management of the disease. Biomarkers, defined as measurable indicators of biological states or conditions, are invaluable for the diagnosis, prognosis and treatment monitoring of TB. Clinical studies have provided critical knowledge on the matter but are also notoriously constrained by economical, ethical and sampling limitations. The use of animal models provides a simpler, more controllable, cost-effective setting with great potential for translation to humans. They also allow the evaluation of biomarkers within the respiratory compartment, when available, which is of particular interest due to the nature of TB pathogenesis. This Review focuses on the current landscape of TB biomarker discovery in several animal models, from invertebrates to large mammals. Here we summarize the basics of host–pathogen immune interaction, describe the main methodological approaches used and highlight the most substantial findings for each animal model studied. Furthermore, we discuss the advantages, challenges and limitations associated with species-specific differences in animal models. We conclude that integrating the data obtained from animal models and human studies is absolutely required to advance the TB field to accelerate the management of this disease., This article is based upon work from COST Action ‘Towards an improvement in diagnostics and treatment strategies for TB control’ (ADVANCE-TB), CA21164, supported by COST (European Cooperation in Science and Technology). This work has been also supported by grants from the Instituto de Salud Carlos III (PI21/00724, PI22/01834 and CP20/00070 to I.L.) integrated in the Plan Nacional I+D+I and co-founded by the ISCIII Subdireccion General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and CERCA Programme/Generalitat de Catalunya. F.J.R. is the recipient of ‘la Caixa’ Foundation grant LCF/PR/HR21-00368, MCIN and ‘ESF Investing in your Future’ grants RYC2019-027799-I/AEI/10.13039/501100011033 and PID2022-139754OB-100, and a Robles Chillida Foundation Grant. The Institute of Agrifood Research and Technology (IRTA) is supported by CERCA Programme/Generalitat de Catalunya. J.B.T. was partially supported by the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation. R.S. is recipient of National Institutes of Health (NIH) awards K01OD031898, R21AI170148 and R56AI184089-01A1, and other institutional grants P30 AI-161943 (Texas D-CFAR). J.B.T. and R.S. are part of IN-TRAC P30AI168439. E.J. and E.T. are recipients of grants from the Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación (AEI), Spain, cofunded by Fondo Europeo de Desarrollo Regional, FEDER, European Union (PID2021-122331OB-I00 and PID2021-125801OB-100) and AGAUR-Generalitat de Catalunya (2021SGR-0092 and 2021SGR-0145). E.J. is a Serra Hunter Fellow., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype

  • Renau-Mínguez, Chantal
  • Herrero-Abadía, Paula
  • Ruiz-Rodríguez, Paula
  • Sentandreu, Vicente
  • Torrents, Eduard
  • Chiner-Oms, Álvaro
  • Torres-Puente, Manuela
  • Comas, Iñaki
  • Julián, Esther
  • Coscollá, Mireia
Mycobacterium brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. Mycobacterium brumae is not pathogenic and it's in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. Mycobacterium brumae genome is composed of a circular chromosome with a high GC content of 69.2% and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. Mycobacterium brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence-related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although the immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae genome is considerably lower than those antigens present in M. bovis BCG genome. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential., This research was funded by the Spanish Ministry of Science, Innovation, and Universities (MICIN) and co-funded by the FEDER Funds (RTI2018-098777-B-I00, RTI2018-094399-A-I00, PID2021-125801OB-I00, PID2021-122331OB-I00, and PID2021-123443OB-I00), the AGAUR-Generalitat of Catalunya (2017SGR229 and 2017SGR-1079), Ramón y Cajal fellowship (RYC-2015-18213 MICIN), FPI fellowship (PRE-2019-088141 MICIN), Generalitat Valenciana (SEJI/2019/011), MycoNET (RED2018-102677-T), and the European Commission—NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Program (PTI+ Salud Global)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multimodal evaluation of drug antibacterial activity reveals cinnamaldehyde analog anti-biofilm effects against Haemophilus influenzae

  • Asensio-López, J.
  • Lázaro-Díez, María
  • Hernández-Cruz, T. M.
  • Blanco-Cabra, N.
  • Sorzabal-Bellido, I.
  • Arroyo-Urea, Eva María
  • Buetas, E.
  • González-Paredes, Ana
  • Ortiz de Solórzano, C.
  • Burgui, S.
  • Torrents, E.
  • Monteserín, M.
  • Garmendia, Juncal
Biofilm formation by the pathobiont Haemophilus influenzae is associated with human nasopharynx colonization, otitis media in children, and chronic respiratory infections in adults suffering from chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD). β-lactam and quinolone antibiotics are commonly used to treat these infections. However, considering the resistance of biofilm-resident bacteria to antibiotic-mediated killing, the use of antibiotics may be insufficient and require being replaced or complemented with novel strategies. Moreover, unlike the standard minimal inhibitory concentration assay used to assess antibacterial activity against planktonic cells, standardization of methods to evaluate anti-biofilm drug activity is limited. In this work, we detail a panel of protocols for systematic analysis of drug antimicrobial effect on bacterial biofilms, customized to evaluate drug effects against H. influenzae biofilms. Testing of two cinnamaldehyde analogs, (E)-trans-2-nonenal and (E)-3-decen-2-one, demonstrated their effectiveness in both H. influenzae inhibition of biofilm formation and eradication or preformed biofilms. Assay complementarity allowed quantifying the dynamics and extent of the inhibitory effects, also observed for ampicillin resistant clinical strains forming biofilms refractory to this antibiotic. Moreover, cinnamaldehyde analog encapsulation into poly(lactic-co-glycolic acid) (PLGA) polymeric nanoparticles allowed drug vehiculization while maintaining efficacy. Overall, we demonstrate the usefulness of cinnamaldehyde analogs against H. influenzae biofilms, present a test panel that can be easily adapted to a wide range of pathogens and drugs, and highlight the benefits of drug nanoencapsulation towards safe controlled release., We are grateful to Alex Mira (FISABIO Foundation, Valencia, Spain) for providing access to the xCELLigence RTCA instrument. Funding Agencies and grant numbers: PhD studentship from Regional Navarra Govern, Spain, reference 0011-1408-2020-000007. Margarita Salas grant from Ministerio de Universidades, Spain, funded by the EU-Next Generation EU. This work has been funded by grants from AEI MICIU RTI2018-096369-B-I00, PID2021-125801OB-I00, MICIU PDI2021- 122409OB-C22; from SEPAR 875/2019; from Gobierno de Navarra PC150-151-152 and PC136-137-138; Atracción de Talento (Modalidad 1) program from Comunidad de Madrid, Spain, 2019-T1/IND-12906; Nanomedicine CSIC Hub, Spain, PIE202180E048. CIBER is an initiative from Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antimicrobial and antibiofilm activity of human recombinant H1 histones against bacterial infections

  • Arévalo-Jaimes, Betsy Verónica
  • Salinas Pena, Mónica
  • Ponte, I.
  • Jordan, Albert
  • Roque, Alicia
  • Torrents, E.
Histones possess significant antimicrobial potential, yet their activity against biofilms remains underexplored. Moreover, concerns regarding adverse effects limit their clinical implementation. We investigated the antibacterial efficacy of human recombinant histone H1 subtypes against Pseudomonas aeruginosa PAO1, both planktonic and in biofilms. After the in vitro tests, toxicity and efficacy were assessed in a P. aeruginosa PAO1 infection model using Galleria mellonella larvae. Histones were also evaluated in combination with ciprofloxacin (Cpx) and gentamicin (Gm). Our results demonstrate antimicrobial activity of all three histones against P. aeruginosa PAO1, with H1.0 and H1.4 showing efficacy at lower concentrations. The bactericidal effect was associated with a mechanism of membrane disruption. In vitro studies using static and dynamic models showed that H1.4 had antibiofilm potential by reducing cell biomass. Neither H1.0 nor H1.4 showed toxicity in G. mellonella larvae, and both increased larvae survival when infected with P. aeruginosa PAO1. Although in vitro synergism was observed between ciprofloxacin and H1.0, no improvement over the antibiotic alone was noted in vivo. Differences in antibacterial and antibiofilm activity were attributed to sequence and structural variations among histone subtypes. Moreover, the efficacy of H1.0 and H1.4 was influenced by the presence and strength of the extracellular matrix. These findings suggest histones hold promise for combating acute and chronic infections caused by pathogens such as P. aeruginosa., This study was partially supported by grants PID2021-125801OB-100, PLEC2022-009356, and PDC2022-133577-I00 to E.T., PID2020-112783GB-C21 to A.J., and PID2020-112783GB-C22 to A.R., funded by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe,” the CERCA programme and AGAUR-Generalitat de Catalunya (2021SGR01545), the European Regional Development Fund (FEDER), and Catalan Cystic Fibrosis association. The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/DI20/11780040.”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Epithelial cells provide immunocompetence to the early embryo for bacterial clearance

  • Roncero-Carol, Joan
  • Olaizola-Muñoa, June
  • Arán, Begoña
  • Sebastiano Mularoni, Loris
  • Miret-Cuesta, Marta
  • Blanco-Cabra, Nuria
  • Casals, Marc
  • Rumbo, Mireia
  • Solé Inarejos, Miquel
  • Ojosnegros, Samuel
  • Alsina, Berta
  • Torrents, E.
  • Veiga, Anna
  • Irimia, Manuel
  • Hoijman, Esteban
Early embryos are exposed to environmental perturbations that may influence their development, including bacteria. Despite lacking a proper immune system, the surface epithelium of early embryos (trophectoderm in mammals) can phagocytose defective pluripotent cells. Here, we explore the dynamic interactions between early embryos and bacteria. Quantitative live imaging of infection models developed in zebrafish embryos reveals the efficient phagocytic capability of surface epithelia in detecting, ingesting, and destroying infiltrated E. coli and S. aureus. In vivo single-cell interferences uncover actin-based epithelial zippering protrusions mediating bacterial phagocytosis, safeguarding developmental robustness upon infection. Transcriptomic and inter-scale dynamic analyses of phagocyte-bacteria interactions identify specific features of this epithelial phagocytic program. Notably, live imaging of mouse and human blastocysts supports a conserved role of the trophectoderm in bacterial phagocytosis. This defensive role of the surface epithelium against bacterial infection provides immunocompetence to early embryos, with relevant implications for understanding failures in human embryogenesis., J.R.-C. acknowledges an FPU fellowship 22/04307 funded by Spanish Ministry of Science and Innovation and an FI fellowship 100057 from AGAUR. E.T. acknowledges funding from MCIN/AEI/10.13039/501100011033 “ERDF A way of making Europe” PID2021-125801OB-100 and AGAUR 2021SGR01545. A.V. acknowledges funding from Instituto de Salud Carlos III (PT23/00092). M.I. acknowledges funding from the Spanish Ministry of Science and Innovation (PID2020-115040GB-I00). E.H. acknowledges support from the Spanish Ministry of Science and Innovation (PID2020-117540GB-I00 and PID2023-151237NB-I00) and the AGAUR (2022-SGR-00974)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The study of immunological markers in tuberculosis across animal models and its translation to human research

  • Díaz-Fernández, Sergio
  • Aleluia, Matilde
  • Saraiva, Margarida
  • Soldevilla, Pablo
  • Torrelles, Jordi B.
  • Sharan, Riti
  • Verreck, Frank A. W.
  • Izzo, Angelo
  • Vidal, Maria
  • Moreira, Ana C.
  • Pérez de Val, Bernat
  • Roca, Francisco Jose
  • Preda, Madalina
  • Torrents, Eduard
  • Julián, Esther
  • Domínguez, José
  • Latorre, Irene
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, remains one of the major causes of death from infection worldwide, with over a million associated deaths each year. The study of biomarkers for TB is critical for advancing our understanding and management of the disease. Biomarkers, defined as measurable indicators of biological states or conditions, are invaluable for the diagnosis, prognosis and treatment monitoring of TB. Clinical studies have provided critical knowledge on the matter but are also notoriously constrained by economical, ethical and sampling limitations. The use of animal models provides a simpler, more controllable, cost-effective setting with great potential for translation to humans. They also allow the evaluation of biomarkers within the respiratory compartment, when available, which is of particular interest due to the nature of TB pathogenesis. This Review focuses on the current landscape of TB biomarker discovery in several animal models, from invertebrates to large mammals. Here we summarize the basics of host–pathogen immune interaction, describe the main methodological approaches used and highlight the most substantial findings for each animal model studied. Furthermore, we discuss the advantages, challenges and limitations associated with species-specific differences in animal models. We conclude that integrating the data obtained from animal models and human studies is absolutely required to advance the TB field to accelerate the management of this disease., This article is based upon work from COST Action ‘Towards an improvement in diagnostics and treatment strategies for TB control’ (ADVANCE-TB), CA21164, supported by COST (European Cooperation in Science and Technology). This work has been also supported by grants from the Instituto de Salud Carlos III (PI21/00724, PI22/01834 and CP20/00070 to I.L.) integrated in the Plan Nacional I+D+I and co-founded by the ISCIII Subdireccion General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and CERCA Programme/Generalitat de Catalunya. F.J.R. is the recipient of ‘la Caixa’ Foundation grant LCF/PR/HR21-00368, MCIN and ‘ESF Investing in your Future’ grants RYC2019-027799-I/AEI/10.13039/501100011033 and PID2022-139754OB-100, and a Robles Chillida Foundation Grant. The Institute of Agrifood Research and Technology (IRTA) is supported by CERCA Programme/Generalitat de Catalunya. J.B.T. was partially supported by the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation. R.S. is recipient of National Institutes of Health (NIH) awards K01OD031898, R21AI170148 and R56AI184089-01A1, and other institutional grants P30 AI-161943 (Texas D-CFAR). J.B.T. and R.S. are part of IN-TRAC P30AI168439. E.J. and E.T. are recipients of grants from the Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación (AEI), Spain, cofunded by Fondo Europeo de Desarrollo Regional, FEDER, European Union (PID2021-122331OB-I00 and PID2021-125801OB-100) and AGAUR-Generalitat de Catalunya (2021SGR-0092 and 2021SGR-0145). E.J. is a Serra Hunter Fellow., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A high-throughput microtiter plate screening assay to quantify and differentiate species in dual-species biofilms

  • Campo Pérez, Víctor|||0000-0003-3161-9984
  • Alcàcer-Almansa, Júlia|||0000-0002-8688-3128
  • Julián, Esther|||0000-0002-6558-3978
  • Torrents, Eduard|||0000-0002-3010-1609
Pathogenic bacteria form biofilms during infection, and polymicrobial biofilms are the most frequent manifestation. Biofilm attachment, maturation, and/or antibiotic sensitivity are mainly evaluated with microtiter plate assays, in which bacteria are stained to enable the quantification of the biomass by optical absorbance or fluorescence emission. However, using these methods to distinguish different species in dual-species or polymicrobial biofilms is currently impossible. Colony-forming unit counts from homogenized dual-species biofilms on selective agar medium allow species differentiation but are time-consuming for a high-throughput screening. Thus, reliable, feasible, and fast methods are urgently needed to study the behavior of polymicrobial and dual-species communities. This study shows that Pseudomonas aeruginosa and Burkholderia cenocepacia strains expressing specific fluorescent or bioluminescent proteins permit the more efficient study of dual-species biofilms compared to other methods that rely on measuring the total biomass. Combining fluorescence and bioluminescence measurements allows an independent analysis of the different microbial species within the biofilm, indicating the degree of presence of each one over time during a dual-species biofilm growth. The quantitative strategies developed in this work are reproducible and recommended for dual-species biofilm studies with high-throughput microtiter plate approaches using strains that can constitutively express fluorescent or bioluminescent proteins.